MediciNova, Inc. (MNOV) is a California-based developer of small-molecule therapeutics. The company was founded and is led by president and CEO Dr. Yuichi Iwaki, M.D., Ph.D., who has several professorships, has authored over 200 peer reviewed publications, and has been advising pharma related entities for over three decades on research and investment strategies. He is also on the board of several biotechnology companies. MediciNova's present focus is on their lead candidate MN-166 (ibudilast) for the treatment of various neurological disorders with unmet medical needs.
What is the drug MN-166
MN-166 is an immunosuppressive